JGC
DAWN

J. Goldman & Co’s Day One Biopharmaceuticals DAWN Stock Holding History

J. Goldman & Co’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-569,619
Closed -$4.02M – 600
2025
Q3 		$4.02M Buy
569,619
+12,139
+2% +$83.5K 0.1% 222
2025
Q2 		$3.62M Buy
+557,480
New +$3.83M 0.09% 228
2024
Q3 		– Sell
-44,943
Closed -$641K – 496
2024
Q2 		$619K Sell
44,943
-16,384
-27% -$240K 0.02% 349
2024
Q1 		$1.01M Buy
+61,327
New +$918K 0.03% 270

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's DAWN Position: Q4 2025 in Review

J. Goldman & Co sold out of Day One Biopharmaceuticals (DAWN) in Q4 2025, closing a stake of 569,619 shares — an estimated $4.02M sold.

J. Goldman & Co first reported a position in DAWN in Q1 2024 and held it in 4 quarters. The position peaked at $4.02M in Q3 2025. 183 funds tracked by Wall St. Rank hold DAWN as of Q4 2025.

  • J. Goldman & Co reported no remaining Day One Biopharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • J. Goldman & Co sold 569,619 Day One Biopharmaceuticals shares in Q4 2025, an estimated $4.02M.
  • J. Goldman & Co first reported a position in Day One Biopharmaceuticals in Q1 2024 and held it in 4 quarters.
  • J. Goldman & Co's Day One Biopharmaceuticals position peaked at $4.02M in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q4 2025.

Based on J. Goldman & Co's 13F filing for Q4 2025, filed 17 Feb 2026.